A5079771075- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Rheumatoid Arthritis Research and Therapies
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Inflammasome and immune disorders
- Systemic Lupus Erythematosus Research
- Ocular Diseases and Behçet’s Syndrome
- Spondyloarthritis Studies and Treatments
- Pediatric health and respiratory diseases
- Orthopedic Infections and Treatments
- Medical and Biological Sciences
- Musculoskeletal Disorders and Rehabilitation
- Kawasaki Disease and Coronary Complications
- Systemic Sclerosis and Related Diseases
- Child and Adolescent Health
- Pneumonia and Respiratory Infections
- Liver Diseases and Immunity
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- Human Health and Disease
- Streptococcal Infections and Treatments
- Osteomyelitis and Bone Disorders Research
- Pharmaceutical studies and practices
Scientific Center of Children's Health
2013-2023
Sechenov University
2021
Center for Children
2018-2020
Ministry of Health of the Russian Federation
2017-2020
Academy of Medical Sciences
2008-2011
Background A significant number of systemic juvenile idiopathic arthritis (sJIA) patients discontinue biologic disease-modifying antirheumatic drugs (bDMARDs) due to lack efficacy or safety concerns. Studies therapy switch regimens in sJIA are required. Methods Patients with who switched from tocilizumab (due safety) canakinumab (4 mg/kg every 4 weeks) and were hospitalized at the rheumatology department August 2012 July 2020 included. Primary outcomes 30% greater improvement based on...
The aim of this study was to investigate the efficacy etanercept treatment and identify predictors response therapy within 12 months in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations.A total 197 were enrolled study. Response assessed using ACRPedi 30/50/70/90 criteria, Wallace Juvenile Arthritis Disease Activity Score 71 (JADAS-71). Univariate multivariate logistic regression analyses performed potential baseline factors associated different JIA...
Remission is the primary objective of treating juvenile idiopathic arthritis (JIA). It still debatable whether early intensive treatment superior in terms earlier achievement remission. The aim this study was to evaluate effectiveness etanercept+methotrexate (ETA+MTX) combination therapy versus step-up MTX monotherapy with ETA added refractory disease. A multi-centre, double-blind, randomized active polyarticular JIA patients treated either ETA+MTX (n = 35) or placebo+MTX 33) for up 24...
The article presents current data on the etiology, pathogenesis, and epidemiology of systemic lupus erythematosus (SLE). SLE diagnosis details are considered with a description each examination technique. Moreover, an assessment reliability level both evidence recommendations for thesis-recommendation discussed thoroughly. aspects differential criteria diagnostic quality revealed.
ObjectivesTo evaluate safety and efficacy of tocilizumab treatment in children with systemic onset juvenile idiopathic arthritis (JIA). MethodsA retrospective observational study on JIA patients taking (n=39).Tocilizumab was administered intravenously at a dose 8 mg/kg every 2 weeks during months then 4 weeks.All received DMARDs.Efficacy end points included the American College Rheumatology (ACR) Pediatric 30 (Pedi 30), Pedi 50, 70, 90 criteria for improvement.
Both the steroid- and NSAID-sparing effects of biologics in juvenile idiopathic arthritis (JIA) treatment are key aspects dynamics patient's condition. The proper selection enables maximum effectiveness reduction dosage concomitant therapy. Our aim was to study therapy during etanercept (ETA) methotrexate (MTX) patients with JIA.This analysis included 215 JIA (63.3% females) showing sufficient response main One hundred received MTX as therapy, 24 ETA monotherapy, 91 þ combination were...
The article describes the monitoring of severe cryopyrin-associated syndrome (syndrome CINCA/NOMID). following clinical case indicates successful application homogeneous antibodies to interleukin 1 — canakinumab in patient with chronic neurologic dermatic articular syndrome. Fever, rush and pain completely jugulated, contractures articulation joints decreased a week since beginning treatment. In 8 weeks therapy movements affected almost restored, boy could stay, spell simple words;...
The results of the retrospective study evaluating efficacy and safety tocilizumab treatment in 75 patients with severe systemic-onset juvenile idiopathic arthritis refractory to standard immunosuppressive therapy are presented paper. Inactive disease was documented 64% after 6 months 73% 12 months. Adverse events manifested as mild moderate infections well laboratory abnormalities: leukopenia, neutropenia, elevated aminotransferase levels.
Background. Blocking of B lymphocytes producing autoantibodies in systemic lupus erythematosus (SLE) may be an effective strategy for pathogenetic treatment, including children. Objective: Our aim was to assess the efficacy and safety rituximab treatment (chimeric monoclonal antibodies CD20) children with severe SLE refractory glucocorticosteroids immunosuppressants. Methods. We studied case histories admitted rheumatology department SCCH between 2004 2013. The results were assessed by...
Background . Patients with juvenile idiopathic arthritis (JIA) have an increased risk of being infected. Approximately half all serious infections in children JIA are associated airway involvement. Objective Our aim was to study the efficacy and safety pneumococcal 13-valent conjugate vaccine (PCV) JIA. Methods. In a prospective cohort study, 5 groups were formed: remission phase on methotrexate therapy (group 1) or etanercept 2), active prior appointment 3) 4), control group (conditionally...
The article presents modern ideas about the treatment of systemic lupus erythematosus (SLE). details management patients with SLE during immunosuppressive and genetically engineered therapy is given. also reflects aspects rehabilitation, prevention exacerbations, follow-up care children SLE. criteria for assessing quality medical are presented. detailed information on their parents outlined specifically.
Objective : Our aim was to study the prevalence and clinical features of autoinflammatory syndromes among patients with systemic juvenile idiopathic arthritis. Methods A prospective nonrandomized conducted. All its members have been studied for mutations in TNFRSF1A NLRP3 genes by sequencing method. Results 90 children (27 boys, 63 girls) aged from 1 17 (average age 8.2) years, a guide diagnosis: «Systemic arthritis», were examined. As result, 10 (14%) showed gene, leading development...
Objective: The aim of this study was to analyze the efficacy and safety etanercept (ETA) in children with juvenile idiopathic arthritis (JIA) under age 4 years compare data those for older groups. Methods: Three groups comprising 34 patients each (total 102 patients) were selected using propensity score matching (PSM) method. group (patients years; Junior (JNR)) compared groups, adjusted criteria such as gender, JIA category, severity, either at disease onset (the Reference by Age Onset...
Aim : to assess efficacy and safety of «changeover» the second genetically engineered biological agent (GEBA) in patients with juvenile idiopathic arthritis (JIA) resistance or intolerability first GEBA. Patients methods results retrospective observational research GEBA 136 various variants JIA aged from 1 17 years old primary resistance, partial effect loss other agents are shown this article. Among those 41 patient have systemic 95 — without extra-articular involvement. In 32 involvement...
This review summarizes the international experience of pneumococcal immunization patients with juvenile idiopathic arthritis (JIA). The high efficiency and safety vaccines in children JIA is shown. Numerous studies have demonstrated an adequate immune response after vaccination even during therapy immunosuppressive genetically engineered biological agents drugs. Prevention infection helps avoid development pneumonia JIA.
<h3>Background</h3> Anti-TNF biologics are highly effective and widely used in clinical practice for the treatment of JIA. However, some children lack response with few reliable predictors a good or poor to found [1–3]. As picture patterns significantly differ 7 JIA subclasses, we propose therapy each category. <h3>Objectives</h3> To identify laboratory parameters associated etanercept 12 months patients different <h3>Methods</h3> Patients from four categories (n=195) were divided groups...
Systemic Juvenile Idiopathic Arthritis (sJIA) is chronic disease. Some patients are resistant to standard immunosupressivetherapy and anti IL6 treatment. of these have autoinflammatory
научный биометрический журнал, который знакомит читателя с клиническими рекомендациями и особенностями применения лекарственных вакцинных средств у детей, предоставляет исчерпывающую информацию о воздействии на плод, проводимых в
Background. To assign genetically engineered biologic drugs, we need data on the predictors for response to therapy. Prognostic factors tocilizumab in patients with juvenile idiopathic arthritis (JIA) without systemic symptoms are poorly studied. Objective. Our aim was reveal early therapy JIA symptoms. Methods. A retrospective cohort study enrolled who received between July 2009 and August 2017. We assessed association initial demographic, clinical, laboratory parameters best (according...
Introduction: In 2011, Etanercept (ETA) was approved for clinical application in patients with Juvenile Idiopathic Arthritis (JIA) older than 2 years of age; Adalimumab (ADA) 2013. However, the available data these are not sufficient even large-scale registers. children, uveitis is a factor taken into consideration when choosing anti-TNF therapy, so we believe that its onset at an early age may affect efficacy treatment different drugs. Objectives: This study aimed to evaluate comparative...
<h3>Background</h3> The use of therapy with anti-cytokine biologicals in routine practice has significantly increased the percentage children showing good response to and reduced time achieve pharmacological remission. Nevertheless, problem related selecting optimal drug for a certain patient still remains be solved. <h3>Objectives</h3> This study was aimed at identifying clinical laboratory parameters associated tocilizumab (TOC) treatment patients RF-negative polyarticular JIA....
International practice of immunization against pneumococcus in patients with systemic juvenile idiopathic arthritis (SJIA) receiving biological therapy is generalized this review. High efficiency and safety pneumococcal vaccines children SJIA presented. Numerous researches show the adequate immune response after vaccination as well alongside genetically engineered biologic drugs therapy. Prevention disease reduces risk development diseases severe complications.
New biologics developed to treat juvenile idiopathic arthritis (JIA) and the broadening range of indications for young children offer new drug switch options if first-line treatment has proved ineffective. Nevertheless, question regarding selection optimal medication depending on patients' characteristics prior therapy still needs be solved. To evaluate efficacy safety adalimumab (ADA) as first subsequent biologic in under 4 years age. Analysis was performed using Research Center Children’s...
Background . Immunological potency of 13-valent pneumococcal vaccine (PCV-13) in children with systemic juvenile idiopathic arthritis (SJIA) is still unstudied. Estimates the genetically engineered biologic drugs (GEBD) effects on vaccination results also remain controversial. Objective The aim study was to explore PCV-13 efficacy patients SJIA and who treatment monoclonal antibodies against interleukin 6 receptor (tocilizumab) 8 beta (canakinumab). Methods included under age 18 remission or...